VFA
PVLA

Virtus Fund Advisers’s Palvella Therapeutics PVLA Stock Holding History

Virtus Fund Advisers’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$432K Buy
+715
New +$332K ﹤0.01% 339

Other funds holding PVLA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Virtus Fund Advisers's PVLA Position: Q4 2017 in Review

Virtus Fund Advisers opened a new position in Palvella Therapeutics (PVLA) in Q4 2017: 715 shares worth $432K. The stake represents ﹤0.01% of the portfolio and ranks #339 among its holdings.

90 funds tracked by Wall St. Rank hold PVLA as of Q4 2017.

  • Virtus Fund Advisers held 715 shares of Palvella Therapeutics worth $432K as of Q4 2017.
  • Palvella Therapeutics was a new Virtus Fund Advisers position in Q4 2017.
  • Palvella Therapeutics made up ﹤0.01% of Virtus Fund Advisers's portfolio in Q4 2017, its #339 holding.
  • 90 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.